TY - JOUR
T1 - Bifunctional antibiotic hybrids
T2 - A review of clinical candidates
AU - Koh, Augustine Jing Jie
AU - Thombare, Varsha
AU - Hussein, Maytham
AU - Rao, Gauri G.
AU - Li, Jian
AU - Velkov, Tony
N1 - Funding Information:
GR, TV, and JL are supported by the National Institute of Allergy and Infectious Diseases, award number R01AI146241. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. TV is an MPT Connect REDI Fellow. JL is a National Australian Health and Medical Research Council Senior Principle Research Fellow.
Funding Information:
GR, TV, and JL are supported by the National Institute of Allergy and Infectious Diseases, award number R01AI146241. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. TV is an MPT Connect REDI Fellow. JL is a National Australian Health and Medical Research Council Senior Principle Research Fellow.
Publisher Copyright:
Copyright © 2023 Koh, Thombare, Hussein, Rao, Li and Velkov.
PY - 2023
Y1 - 2023
N2 - Antibiotic resistance is a top threat to human health and a priority across the globe. This problematic issue is accompanied by the decline of new antibiotics in the pipeline over the past 30 years. In this context, an urgent need to develop new strategies to combat antimicrobial resistance is in great demand. Lately, among the possible approaches used to deal with antimicrobial resistance is the covalent ligation of two antibiotic pharmacophores that target the bacterial cells through a dissimilar mode of action into a single hybrid molecule, namely hybrid antibiotics. This strategy exhibits several advantages, including better antibacterial activity, overcoming the existing resistance towards individual antibiotics, and may ultimately delay the onset of bacterial resistance. This review sheds light on the latest development of the dual antibiotic hybrids pipeline, their potential mechanisms of action, and challenges in their use.
AB - Antibiotic resistance is a top threat to human health and a priority across the globe. This problematic issue is accompanied by the decline of new antibiotics in the pipeline over the past 30 years. In this context, an urgent need to develop new strategies to combat antimicrobial resistance is in great demand. Lately, among the possible approaches used to deal with antimicrobial resistance is the covalent ligation of two antibiotic pharmacophores that target the bacterial cells through a dissimilar mode of action into a single hybrid molecule, namely hybrid antibiotics. This strategy exhibits several advantages, including better antibacterial activity, overcoming the existing resistance towards individual antibiotics, and may ultimately delay the onset of bacterial resistance. This review sheds light on the latest development of the dual antibiotic hybrids pipeline, their potential mechanisms of action, and challenges in their use.
KW - antibiotic pipeline
KW - antibiotic resistance
KW - drug combinations
KW - drug synthesis
KW - hybrid antibiotics
UR - http://www.scopus.com/inward/record.url?scp=85164449438&partnerID=8YFLogxK
U2 - 10.3389/fphar.2023.1158152
DO - 10.3389/fphar.2023.1158152
M3 - Review Article
C2 - 37397488
AN - SCOPUS:85164449438
SN - 1663-9812
VL - 14
JO - Frontiers in Pharmacology
JF - Frontiers in Pharmacology
M1 - 1158152
ER -
